Wethington SL, Shah PD, Martin L, Tanyi JL, et al. Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer. Clin Cancer Res 2023 Apr 25:CCR-22-2444. doi: 10.1158/1078-0432.CCR-22-2444.
PMID: 37097611